Eargo, Inc. (EAR)
|Net Income (ttm)||-43.83M|
|Trading Day||January 25|
|Day's Range||56.57 - 63.70|
|52-Week Range||33.49 - 63.70|
Eargo Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Net Revenue and Preliminary Gross Systems Shipped
SAN JOSE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced...
SAN JOSE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announce...
Eargo is also named to “Best Company for Women” and “Best CEOs” list Eargo is also named to “Best Company for Women” and “Best CEOs” list
Deep Pharma Intelligence Names Nanox, TransMedics, Outset, Eargo, and Silkroad as Best Health-Tech Companies to Watch in 2021-2022
LONDON--(BUSINESS WIRE)--Deep Pharma Intelligence names Nanox Imaging (NASDAQ:NNOX), TransMedics, Inc. (NASDAQ: TMDX), Outset Medical, Inc. (NASDAQ:OM), Eargo, Inc. (NASDAQ:EAR), and Silk Road...
Net revenues of $18.2 million, up 135.3% year-over-year
SAN JOSE, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Eargo Inc., (NASDAQ: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced...
Eargo is a medical device company dedicated to improving the quality of life of people with hearing loss. We developed the Eargo solution to create a hearing aid that consumers actually want to use. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost. We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA regulated, exempt Class I device for the treatment of hearing loss. Ou... [Read more...]
|IPO Date |
Oct 16, 2020
|Stock Exchange |
|Ticker Symbol |
In 2019, Eargo's revenue was $32.79 million, an increase of 41.56% compared to the previous year's $23.16 million. Losses were -$44.49 million, 31.6% more than in 2018.
According to 4 analysts, the average rating for Eargo stock is "Strong Buy." The 12-month stock price forecast is 52.33, which is a decrease of -15.17% from the latest price.